Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

United Therapeutics (UTHR) EBT (2016 - 2025)

United Therapeutics (UTHR) has disclosed EBT for 17 consecutive years, with $444.0 million as the latest value for Q4 2025.

  • Quarterly EBT rose 11.98% to $444.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.7 billion through Dec 2025, up 11.36% year-over-year, with the annual reading at $1.7 billion for FY2025, 11.36% up from the prior year.
  • EBT hit $444.0 million in Q4 2025 for United Therapeutics, up from $438.0 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $444.0 million in Q4 2025 to a low of $32.5 million in Q1 2021.
  • Historically, EBT has averaged $303.6 million across 5 years, with a median of $323.8 million in 2022.
  • Biggest five-year swings in EBT: crashed 81.06% in 2021 and later skyrocketed 849.85% in 2022.
  • Year by year, EBT stood at $140.5 million in 2021, then increased by 27.26% to $178.8 million in 2022, then soared by 65.21% to $295.4 million in 2023, then soared by 34.22% to $396.5 million in 2024, then grew by 11.98% to $444.0 million in 2025.
  • Business Quant data shows EBT for UTHR at $444.0 million in Q4 2025, $438.0 million in Q3 2025, and $408.4 million in Q2 2025.